Sugi Predict

Sugi Predict / Compounds / SCHEMBL14645401

SCHEMBL14645401

SCHEMBL14645401

COC(=O)c1ccc(-c2cc(CC(=O)O)c(-c3ccc(-c4sc(-c5ccc(C(=O)OC)s5)cc4CC(=O)O)s3)s2)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ NCOA2 Q15596 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ HPGD P15428 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ FAAH O00519 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ TP53 P04637 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RXFP1 Q9HBX9 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15695277 0.90 LMNA (0.35) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL9976532 0.88 POLB (0.41) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL14646131 0.88 POLB (0.41) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL14645296 0.88 POLB (0.41) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL14646273 0.88 POLB (0.41) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL14646206 0.88 POLB (0.41) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL9976534 0.84 HPGD (0.40) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL14645525 0.83 NPSR1 (0.37) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL26509198 0.83 DAO (0.47) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL15695246 0.83 HPGD (0.43) HPGDALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 — — EP disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 — — WO disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 NPSR1 2158/4885LMNA 262/4885PPARG 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.